IMZ Advisory Inc Makes New $284,000 Investment in Johnson & Johnson (NYSE:JNJ)

IMZ Advisory Inc acquired a new stake in Johnson & Johnson (NYSE:JNJ - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,712 shares of the company's stock, valued at approximately $284,000.

Several other hedge funds also recently bought and sold shares of the stock. Sweeney & Michel LLC purchased a new position in Johnson & Johnson during the first quarter worth about $5,726,000. Fragasso Financial Advisors Inc boosted its stake in Johnson & Johnson by 109.4% during the first quarter. Fragasso Financial Advisors Inc now owns 27,838 shares of the company's stock worth $4,617,000 after buying an additional 14,543 shares during the period. NBC Securities Inc. boosted its stake in Johnson & Johnson by 102,995.0% during the first quarter. NBC Securities Inc. now owns 41,238 shares of the company's stock worth $6,838,000 after buying an additional 41,198 shares during the period. Enterprise Bank & Trust Co boosted its stake in Johnson & Johnson by 3.6% during the first quarter. Enterprise Bank & Trust Co now owns 5,283 shares of the company's stock worth $876,000 after buying an additional 185 shares during the period. Finally, Worth Asset Management LLC boosted its stake in Johnson & Johnson by 49.0% during the first quarter. Worth Asset Management LLC now owns 2,391 shares of the company's stock worth $396,000 after buying an additional 786 shares during the period. Hedge funds and other institutional investors own 69.55% of the company's stock.

Wall Street Analysts Forecast Growth

JNJ has been the subject of several recent research reports. Barclays lowered their price objective on shares of Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating for the company in a research note on Thursday, April 17th. Sanford C. Bernstein reissued a "market perform" rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. Royal Bank of Canada restated an "outperform" rating and set a $181.00 target price on shares of Johnson & Johnson in a research report on Thursday. The Goldman Sachs Group upgraded shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and raised their target price for the stock from $157.00 to $172.00 in a research report on Wednesday, April 9th. Finally, Guggenheim reiterated a "neutral" rating on shares of Johnson & Johnson in a research report on Wednesday, April 2nd. Eleven research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $170.88.

Johnson & Johnson Price Performance

JNJ stock traded up $0.02 during trading on Thursday, hitting $153.24. The stock had a trading volume of 2,175,999 shares, compared to its average volume of 7,917,384. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $169.99. The company's 50 day moving average price is $153.81 and its two-hundred day moving average price is $153.67. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. The stock has a market cap of $368.71 billion, a price-to-earnings ratio of 23.04, a price-to-earnings-growth ratio of 2.56 and a beta of 0.42.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, beating analysts' consensus estimates of $2.59 by $0.18. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The company had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. On average, sell-side analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th will be given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.39%. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date of this dividend is Tuesday, May 27th. Johnson & Johnson's dividend payout ratio is presently 57.84%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.